Stryker's OP-I implant nears Australian approval:
This article was originally published in Clinica
The Australian Drug Evaluation Committee has recommended that Stryker's OP-1 Implant be approved for the treatment of non-union long bone fractures secondary to trauma. The implant, licensed from Curis, has already received a similar recommendation in Europe, although the US FDA recently declined to grant approval. A final decision by the Australian Therapeutic Goods Agency is expected within three months.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.